BRAF and colorectal carcinoma: Even though they result generally in a significantly better overall survival (OS) (median 62.0 vs. 12.6 months; HR 0.36, p = 0.002) [65,66], non-V600E-BRAF-mutated CRC can be subdivided in two classes, with respect to their anti-EGFR treatment response, the RAS-independent activating (class 2) and the RAS-dependent activating non-V600E-BRAF mutation (class 3) [67].